Telaprevir for chronic HCV infection

New England Journal of Medicine

Volumn 361, Issue 5, 2009, Pages 533-535

  Van Der Meer, Adriaan J P ^a   De Knegt, Robert J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PROTEINASE INHIBITOR; TELAPREVIR; VIRUS RNA;

ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; TREATMENT WITHDRAWAL;

EID: 68049139715     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc091186     Document Type: Letter

References (4)

1. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838.
2. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-1850.
3. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002. (Pubitemid 44498690)
4. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46:631-639 (Pubitemid 47436107)